Development and characterization of TrMab‑6, a novel anti‑TROP2 monoclonal antibody for antigen detection in breast cancer
- Yusuke Sayama
- Mika K. Kaneko
- Yukinari Kato
Affiliations: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan
- Published online on: November 25, 2020 https://doi.org/10.3892/mmr.2020.11731
Copyright : © Sayama
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License [CC BY 4.0].
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Trophoblast cell‑surface antigen 2 (TROP2) is a type I transmembrane glycoprotein that is overexpressed in a number of cancer types, including triple‑negative breast cancer. The current study aimed to develop a highly sensitive and specific monoclonal antibody (mAb) targeting TROP2, which could be used to evaluate TROP2 expression using flow cytometry, western blot analysis and immunohistochemistry by employing the Cell‑Based Immunization and Screening (CBIS) method. The established anti‑TROP2 mAb, TrMab‑6 (mouse IgG2b, κ), detected TROP2 on PA‑tagged TROP2‑overexpressing Chinese hamster ovary‑K1 (CHO/TROP2‑PA) and breast cancer cell lines, including MCF7 and BT‑474 using flow cytometry. Western blot analysis indicated a 40 kDa band in lysates prepared from CHO/TROP2‑PA, MCF7 and BT‑474 cells. Furthermore, TROP2 in 57/61 (93.4%) of the breast cancer specimens was strongly detected using immunohistochemical analysis with TrMab‑6. In conclusion, the current study demonstrated that TrMab‑6 may be a valuable tool for the detection of TROP2 in a wide variety of breast cancer types.